Joyce Judith M, Swihart Andrew
Division of Nuclear Medicine, Department of Radiology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Radiol Clin North Am. 2011 May;49(3):425-34, v. doi: 10.1016/j.rcl.2011.02.004.
Nuclear medicine has been used in the evaluation and treatment of benign and malignant thyroid disease since the discovery of iodine 131 ((131)I) in the 1930s. Although traditional methods of imaging are routinely used, recent advancements such as SPECT/CT and PET/CT have greatly enhanced the ability of nuclear medicine to accurately detect and localize. Guidelines for the management of thyroid cancer continue to evolve, treatment regimens selected should balance the long-term risk of disease recurrence and cumulative risks of radiation exposure, and physicians should be aware of these updates and guidelines when caring for patients with thyroid disease.
自20世纪30年代发现碘131（¹³¹I）以来，核医学一直用于评估和治疗良性及恶性甲状腺疾病。尽管传统成像方法仍在常规使用，但诸如SPECT/CT和PET/CT等最新进展极大地提高了核医学准确检测和定位的能力。甲状腺癌的管理指南不断发展，所选治疗方案应平衡疾病复发的长期风险和辐射暴露的累积风险，医生在治疗甲状腺疾病患者时应了解这些更新和指南。
